• Lycopene, the plant nutrient which creates the red pigment in tomatoes, was identified for the first time, though scientists were uncertain about its precise health benefits.

  • Scientists began to notice that people who had high levels of lycopene in their blood, seemed to be better protected against cancer and heart disease.

  • German scientists in Dusseldorf found lycopene also protected people from heart disease and cataracts.

  • Italian scientists compared blood lycopene levels in 2,706 men suffering from five different types of digestive tract cancer with 2,879 cancer-free men of the same age and background over six years. Their results published in the International Journal of Cancer, showed high levels of blood lycopene protected against these types of cancer.

  • Scientists in Vancouver noticed a link between high blood lycopene and protection from prostate cancer, and called for more research to identify the protective mechanism

    Growing excitement about the role of lycopene in prevention of all sorts of diseases, led to the first ever international symposium in New York, to discuss how doctors and patients could make use of the new findings.

    The same Dusseldorf group, wrestling with the problem of how to boost natural lycopene levels in the human body, announced it was better absorbed from tomato paste than from fresh tomatoes.

  • The Ateronon breakthrough

    Scientists working for the Nestle food research centre in Lausanne, Switzerland, announced they had found a way to reduce the size of lycopene molecules by combining them with a milk whey protein called lactose. The new formula meant lycopene absorption was dramatically improved. It was named LactoLycopene and quickly patented.

  • Ateronon obtains the license to incorporate LactoLycopene technology and along with funding from the British Heart Foundation, £10m was committed to develop the an encapsulated formulation. Senior scientists were then signed up to generate research evidence of its protective properties.

  • Ateronon is launched at the British Cardiology Conference in London and makes national and international front page news as well as being heavily featured on TV and radio.

  • Ateronon taken on by Cambridge Nutraceuticals, which raised further funding to complete the research started at Harvard and Cambridge Universities.

  • Cambridge scientists announced evidence that Ateronon improves blood vessel flexibility, in a presentation to the American Heart Association.

  • New research contracts have been signed with Harvard and Cambridge Universities. Negotiations with research coordinators at Birmingham University, are ongoing.

  • Study at Cambridge University demonstrating that Ateronon increases arterial flexibility by 53% is published in PLOSone journal. The study receives global media attention, and headlined with front page coverage in UK national newspapers.

    A symposium about Ateronon and lycopene research is presented at the British Cardiovascular Conference.

  • The company launches two new products, Ateronon XY and Ateronon ACTIVE. Both feature increased bioavailability of active ingredients.

    Ateronon commissions study linking blood lycopene levels with prostate health.

    Research on Ateronon Active bioavailable curcumin formulation to be presented at the Football Medicines Strategy Conference in London. This followed the publication of a study linking curcumin with relief from delayed onset muscle soreness in November 2014.